Over the past 12‑18 months the CAR‑T Cellular Immunotherapy industry trends have accelerated, driven by strategic alliances, high‑profile M&A, and regulatory momentum. In Q2 2024, Novartis and Allogene Therapeutics announced a co‑development pact to combine Novartis’ manufacturing platform with Allogene’s off‑the‑shelf allogeneic CAR‑T candidates, aiming to cut time‑to‑patient by 30%. Meanwhile, Bristol‑Myers Squibb completed its $1.2 billion acquisition of Juno Therapeutics’ CAR‑T pipeline, expanding its portfolio into solid‑tumor indications. The FDA’s 2024 guidance on decentralized manufacturing cleared the path for regional cell‑processing hubs, prompting several biotech firms to secure Series C funding ranging from $150 million to $250 million. Consumer‑centric trends are also shifting, with hospitals adopting outpatient infusion models that reduce length of stay and cost. These dynamics collectively reshape market forecasts and set the stage for broader adoption across hematologic and solid‑tumor therapies. In early 2024, Kite Gyre introduced KTE‑X19b, a next‑generation CD19 CAR‑T with a safety‑switch module, receiving accelerated approval for relapsed‑refractory mantle‑cell lymphoma. Additionally, Cellectis opened a 40,000‑sq‑ft GMP facility in Singapore to serve Asia‑Pacific customers, underscoring geographic expansion.
